18:11 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Autolus raises $150M in upsized IPO

Autolus Therapeutics plc (NASDAQ:AUTL) climbed $8 (47%) to $25 its first day of trading on June 22 after it raised $150 million via the sale of 8.8 million ADSs at $17 in an upsized IPO....
02:56 , Jun 22, 2018 |  BC Extra  |  Financial News

First-day bump for Autolus after pricing $150M IPO

Autolus Therapeutics plc (NASDAQ:AUTL) climbed $8 (47%) to $25 its first day of trading Friday after it raised $150 million via the sale of 8.8 million ADSs at $17 in an upsized IPO. Underwriters are...
19:32 , Jun 15, 2018 |  BC Week In Review  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing June 8, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS...
13:09 , Jun 8, 2018 |  BC Extra  |  Financial News

Autolus proposes IPO terms

Cell therapy developer Autolus Therapeutics Ltd. (London, U.K.) revealed terms for its proposed IPO on NASDAQ. In a regulatory filing Friday, the company proposed to sell 7.8 million ADSs at $15-$17, with each ADS representing...
19:18 , Apr 27, 2018 |  BC Week In Review  |  Company News

Autolus, UCL in CAR T deal

UCL Business plc (London, U.K.) granted Autolus Ltd. (London, U.K.) worldwide rights to develop and commercialize CD19 CAR T cell therapy AUTO1 to treat B cell malignancies. Autolus said AUTO1 has a binder with an equivalent...
20:43 , Apr 23, 2018 |  BC Extra  |  Company News

Autolus, UCL in CAR T deal

UCL Business plc (London, U.K.) granted Autolus Ltd. (London, U.K.) worldwide rights to develop and commercialize CD19 CAR T cell therapy AUTO1 to treat B cell malignancies. Autolus said AUTO1 has a binder with an...